ArticleCancer research2017
β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The Coming of Age of Preclinical Models of MDS.Frontiers in oncology · 2022Pooled it
- Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).Annals of hematology · 2021Trial
- β-Catenin interacts with canonical RBPs including MSI2 to associate with a Wnt signalling mRNA network in myeloid leukaemia cells.Oncogene · 2025Article
- [Mechanisms by which the bone marrow microenvironment of myelodysplastic neoplasms contributes to disease progression].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.EBioMedicine · 2022Article
- Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives.Bioscience reports · 2022Review
- Canonical Wnt: a safeguard and threat for erythropoiesis.Blood advances · 2021Review
- Article
- Therapeutic Vulnerabilities of Transcription Factors in AML.Molecular cancer therapeutics · 2021Review
- Bone marrow niches in myelodysplastic syndromes.Journal of cancer metastasis and treatment · 2021Article
- Targeting Casein Kinase 1 (CK1) in Hematological Cancers.International journal of molecular sciences · 2020Review
- Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment.International journal of molecular sciences · 2020Review
- LEF-1 drives aberrant β-catenin nuclear localization in myeloid leukemia cells.Haematologica · 2019Article
- Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.Leukemia · 2019Article
- Driver genes exome sequencing reveals distinct variants in African Americans with colorectal neoplasia.Oncotarget · 2019Article
- The human adrenal cortex: growth control and disorders.Clinics (Sao Paulo, Brazil) · 2018Review
- An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS.Leukemia · 2018Article
- Article
- The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Deletion of the chromosome 5q [del(5q)] is one of the most common cytogenetic abnormalities observed in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.